SMLR News Alert Semler Scientific Inc. (SMLR) 2.92 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 13, 2014 at 6:03 AM

Semler Scientific Inc. (SMLR) 2.92 $SMLR

Semler Scientific, Inc. Presentation Now Available for On-Demand viewing at VirtualInvestorConferences.com
CNW Group - Mon Dec 08, 7:30AM CST
Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"

, an emerging medical risk assessment company that develops patented products to assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced that the December 4th presentation from Doug Murphy-Chutorian, M.D., chief executive officer of Semler, is now available for on-demand viewing at VirtualInvestorConferences.com.
SMLR: 2.92 (+0.07)

Eight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com
CNW Group - Tue Dec 02, 7:29AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
SMLR: 2.92 (+0.07), ONVO: 6.35 (+0.85), CYTX: 0.53 (+0.05), IAG: 2.57 (+0.06)

Semler Scientific, Inc., to Webcast, Live, at VirtualInvestorConferences.com December 4th
PR Newswire - Fri Nov 21, 7:30AM CST
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
SMLR: 2.92 (+0.07)

Semler incurs higher net loss of USD1.466m for Q3 2014
M2 - Mon Nov 03, 6:13AM CST
Medical risk company Semler Scientific (Nasdaq:SMLR) disclosed on Friday its net loss of USD1.466m (USD0.31 per share) for the third quarter ended 30 September 2014.
SMLR: 2.92 (+0.07)

Semler Scientific's (SMLR) CEO Doug Murphy-Chutorian on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 31, 11:38AM CDT

SMLR: 2.92 (+0.07)

Semler Scientific misses by $0.08, revenue in-line
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 7:10AM CDT

SMLR: 2.92 (+0.07)

Semler Reports Third Quarter 2014 Financial Results
PR Newswire - Fri Oct 31, 7:00AM CDT
Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"

, an emerging medical risk assessment company that develops patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today reported financial results for the third quarter and nine months ended September 30, 2014.
SMLR: 2.92 (+0.07)

Semler to Report Third Quarter 2014 Financial Results and Host Conference Call on October 31, 2014
PR Newswire - Wed Oct 22, 11:22AM CDT
Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"

, an emerging medical risk assessment company that develops patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced that it will report third quarter 2014 financial results before the open of U.S. financial markets on October 31, 2014. Doug Murphy-Chutorian, M.D., chief executive officer of Semler, will host a conference call at 11 a.m. EDT on October 31, 2014.
SMLR: 2.92 (+0.07)

Semler Reports Second Quarter 2014 Financial Results
PR Newswire - Fri Jul 25, 7:00AM CDT
Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"

, an emerging medical risk assessment company that develops patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today reported financial results for the second quarter and six months ended June 30, 2014.
SMLR: 2.92 (+0.07)

Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014
PR Newswire - Tue Jul 22, 7:00AM CDT
Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"

, an emerging medical risk assessment company that develops patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced that it will report second quarter 2014 financial results before the open of U.S. financial markets on July 25, 2014. Doug Murphy-Chutorian, M.D., chief executive officer of Semler will host a conference call at 11 a.m. EDT, July 25, 2014.
SMLR: 2.92 (+0.07)

Semler Scientific, Inc. Appoints Risk Management and Business Development Expert Aidan M. Collins to its Board of Directors and Chairman of the Audit Committee
PR Newswire - Tue Jul 08, 7:00AM CDT
Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"

, an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced the appointment of Aidan M. Collins to the company's board of directors and as chairman of the audit committee. With an extensive career in healthcare risk management and business development, Mr. Collins brings a wide range of expertise in strategic, operational and financial management to the Semler team.
SMLR: 2.92 (+0.07)

Semler Scientific, Inc. Appoints Managed Care Leader Abbie Leibowitz, M.D., to its Board of Directors
PR Newswire - Thu Jun 26, 7:00AM CDT
Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"

, an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced the appointment of Arthur "Abbie" Leibowitz, M.D., F.A.A.P., to the company's board of directors. Dr. Leibowitz is an expert in managed care, health benefits and insurance, and has extensive experience in the assessment of coverage of new technologies by large health plans. He has also authored numerous articles and book chapters on population health management.
SMLR: 2.92 (+0.07)

Semler Scientific, Inc. Appoints Scott Ashworth to Position of Executive Vice President of Global Sales
PR Newswire - Tue Jun 24, 7:00AM CDT
Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

MV Transportation Celebrates Leadership Nomination for FTA

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

LaserAway Expands to 244 Clinics Over 20 Years

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...